Pfizer halts Gleevec replacement trial after early success

02/2/2005 | iWon

Pfizer decided to stop the trial for its SU11248 drug for treating stomach cancer after the drug was proven effective by meeting its efficacy targets. SU11248 appears to be a viable replacement for Novartis' Gleevec, the current standard treatment that is ineffective in some patients. An analyst said the early success means Pfizer could receive approval as early as this year.

View Full Article in:

iWon

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL